<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15260010
   </pmid>
   <datecreated>
    <year>
     2004
    </year>
    <month>
     07
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     08
    </month>
    <day>
     05
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     01
    </month>
    <day>
     20
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1530-891X
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       8
      </volume>
      <issue>
       6
      </issue>
      <pubdate>
       <medlinedate>
        2002 Nov-Dec
       </medlinedate>
      </pubdate>
     </journalissue>
     <title>
      Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
     </title>
     <isoabbreviation>
      Endocr Pract
     </isoabbreviation>
    </journal>
    <articletitle>
     American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update.
    </articletitle>
    <pagination>
     <medlinepgn>
      440-56
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      In these clinical practice guidelines, specific recommendations are made for determining the most effective methods of diagnosing and treating hypogonadism in adult male patients. The target populations for these guidelines include the following: (1) men with primary testicular failure requiring testosterone replacement (hypergonadotropic hypogonadism); (2) male patients with gonadotropin deficiency or dysfunction who may have received testosterone replacement therapy or treatment for infertility (hypogonadotropic hypogonadism); and (3) aging men with symptoms relating to testosterone deficiency who could benefit from testosterone replacement therapy. Initial hormonal evaluation generally consists of a testosterone determination, in conjunction with a free testosterone or sex hormone-binding globulin level, inpatients with clear symptoms and signs but normal-range total testosterone, follicle-stimulating hormone, luteinizing hormone, and prolactin levels. Other possible tests include semen analysis, pituitary imaging studies, genetic studies, bone densitometry, testicular ultrasonography,testicular biopsy, and specialized hormonal dynamic testing. Therapeutic options generally consist of testosterone replacement by injections, patches, or topically applied gel in hypergonadotropic patients and in hypogonadotropic patients not interested in fertility. In hypogonadotropic patients interested in fertility, gonadal stimulation option scan be considered, including human chorionic gonadotropin stimulation therapy with or without human menopausal gonadotropin (or follicle-stimulating hormone) or gonadotropin-releasing hormone pump therapy. These therapies may be combined with assisted reproductive technologies such as in vitro fertilization with intracytoplasmic sperm injection, which may allow pregnancy to occur with very low numbers of sperm.
     </abstracttext>
    </abstract>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Petak
      </lastname>
      <forename>
       Steven M
      </forename>
      <initials>
       SM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Nankin
      </lastname>
      <forename>
       Howard R
      </forename>
      <initials>
       HR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Spark
      </lastname>
      <forename>
       Richard F
      </forename>
      <initials>
       RF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Swerdloff
      </lastname>
      <forename>
       Ronald S
      </forename>
      <initials>
       RS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Rodriguez-Rigau
      </lastname>
      <forename>
       Luis J
      </forename>
      <initials>
       LJ
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       American Association of Clinical Endocrinologists
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Guideline
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Practice Guideline
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Endocr Pract
    </medlineta>
    <nlmuniqueid>
     9607439
    </nlmuniqueid>
    <issnlinking>
     1530-891X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Gonadotropins
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      12629-01-5
     </registrynumber>
     <nameofsubstance>
      Human Growth Hormone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      33515-09-2
     </registrynumber>
     <nameofsubstance>
      Gonadotropin-Releasing Hormone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      58-22-0
     </registrynumber>
     <nameofsubstance>
      Testosterone
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="ErratumIn">
     <refsource>
      Endocr Pract. 2008 Sep;14(6):802-3
     </refsource>
     <note>
      Petak, Steven M [added]; Nankin, Howard R [added]; Spark, Richard F [added]; Swerdloff, Ronald S [added]; Rodriguez-Rigau, Luis J [added]
     </note>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aging
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bone Density
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diagnosis, Differential
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gonadotropin-Releasing Hormone
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gonadotropins
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Human Growth Hormone
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypogonadism
     </descriptorname>
     <qualifiername majortopicyn="Y">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="N">
      genetics
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Physical Examination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pituitary Gland
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Testis
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Testosterone
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2004
     </year>
     <month>
      7
     </month>
     <day>
      21
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      8
     </month>
     <day>
      6
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2004
     </year>
     <month>
      7
     </month>
     <day>
      21
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     15260010
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

